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Reactivation of telomerase, an enzyme which elongates human telomeres, is associated with cell
immortilization. In approximately 90% of malignant tumours telomerase activity can be
demonstrated, whereas in benign tumours it is mostly absent. Chondrosarcomas are relatively
rare malignant cartilaginous neoplasms. A small number of chondrosarcomas located centrally in
bone arise secondarily to an enchondroma, while the majority of chondrosarcomas developing
from the surface arise within the cartilage cap of an osteochondroma. The histological distinction
between a benign lesion and low-grade chondrosarcoma is generally considered dif®cult. To
investigate whether the progression towards chondrosarcoma is characterized by reactivation of
telomerase activity, this study determined telomerase activity in ten enchondromas, ®ve
osteochondromas, and 37 chondrosarcomas using the TRAP assay. In all tumour samples
except one, telomerase activity was absent. By adding tumour lysates to the positive control, an
increasing inhibition of telomerase activity was found with an increasing chondroid matrix,
suggesting that it may contain inhibitory factors. Inhibition due to endogenous RNAse or Taq-
polymerase inhibitors was excluded. The lack of detectable telomerase activity in the high-grade
component of a dedifferentiated chondrosarcoma without matrix favours the possibility that
telomerase is truly absent. Either its true absence or inhibitory effects disabling telomerase
detection exclude the telomerase TRAP assay as a diagnostic tool in the differential diagnosis of
benign and low-grade malignant cartilaginous tumours. Copyright # 2000 John Wiley & Sons,
Ltd.
Keywords: telomerase; chondrosarcoma; enchondroma; osteochondroma; bone neoplasms
Introduction
Human telomeres are specialized structures constitut-
ing the ends of the eukaryotic chromosomes, consisting
of TTAGGG repeats. Telomere integrity is important
to maintain the stability of chromosomal ends,
protecting chromosomes from recombination and
loss. Telomeres shorten with each round of replication,
since DNA polymerase cannot replicate the very end of
a linear DNA molecule (the so-called `end replication
problem') [1,2]. Telomere loss has been suggested as a
regulatory mechanism controlling the number of times
a cell can divide before undergoing cellular senescence
[1,2].
The maintenance of telomere length is associated
with the re-expression of telomerase, a ribonucleopro-
tein with a reverse transcriptase activity that synthe-
sizes TTAGGG telomeric repeat sequences, which are
fused to the 3k terminus of the chromosome. In
immortal cell lines, germ cells (as in adult testis and
ovaries), and proliferative cells of renewal tissues (such
as activated lymphocytes), telomerase activity can be
detected. Similarly, in malignant cells telomere length
is maintained by telomerase, resulting in an immortal
phenotype. Essentially all major types of cancer have
been screened and the presence of telomerase activity
has been detected in about 90% of cases [3]. In most
somatic tissues and benign neoplasms, telomerase
activity is absent [3]. A series of cartilaginous tumour
samples has so far not been investigated.
Chondrosarcomas are malignant cartilage-forming
tumours, presenting on average between 35 and 60
years of age. This is the second most frequent primary
malignant bone tumour after osteosarcoma. Chondro-
sarcomas are slow-growing tumours characterized by
the late development of metastases. It is considered
dif®cult to assess the histological grade of cartilaginous
tumours and to distinguish between benign tumours
(enchondroma and osteochondroma) and those of low-
grade malignancy [4]. The term `borderline chondro-
sarcoma' was introduced for those cases where
histological features are not suf®cient to diagnose
grade I chondrosarcoma, while X-rays show features
of an aggressive neoplasm [5].
Only a small number of chondrosarcomas located
centrally in bone (central chondrosarcomas) arise
secondarily to an enchondroma, often in patients
demonstrating non-hereditary multiple enchondromas
(Ollier's disease or Maffucci's syndrome) [6]. The
majority of chondrosarcomas developing from the
surface of bone (peripheral chondrosarcoma) arise
within the cartilage cap of a long-standing
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osteochondroma (exostosis) [6,7], mostly in patients
suffering from hereditary multiple exostoses (HME).
HME is a familial disorder with an autosomal
dominant mode of inheritance [8,9]. Malignant trans-
formation is estimated to occur in 1±5% of cases.
So far, no diagnostic immunohistochemical or
molecular genetic markers have been de®ned to help
discriminate between benign and malignant tumours.
We therefore determined telomerase activity in enchon-
dromas, osteochondromas, and chondrosarcomas,
including chondrosarcoma metastases, to investigate
whether telomerase activity is reactivated during the




Fifty-two representative tissue samples of benign
(n=15), borderline (n=8), and malignant (n=29)
cartilaginous tumours were snap-frozen in 2-butanol
on liquid carbon dioxide directly after surgery and
stored at x80uC. Tumour samples had been collected
over the past 8 years. Chondrosarcomas developing
centrally in bone (within the medullary cavity) as well
as peripherally (from the cortex) were both included
(Table 1). Examples are shown in Figure 1. Patient
data were obtained by review of pathology specimens
and reports, clinical charts, and radiographs. Central
and peripheral chondrosarcomas were identi®ed based
on accepted clinico-pathological and radiological cri-
teria [10]. Four central chondrosarcomas were second-
ary to an enchondroma [4], while all peripheral
chondrosarcomas had developed within a pre-existing
osteochondroma. Haematoxylin and eosin-stained
cryostat sections were used to con®rm the presence of
viable cartilaginous tumour tissue. The amount of
cartilaginous matrix was estimated as a percentage
from the total surface area of the tissue slide and
cellularity (including normal contaminating cells such
as bone marrow) was semiquantitatively assessed by
two observers independently.
In addition, we included two chondrosarcoma cell
lines [SW-1353 (H5B-94, American Type Cell Cultures,
Rockville, MD, USA) and OUMS-27 [11]], as well as a
cell culture of a high-grade recurrent chondrosarcoma
(99-389-1) [conditions as described [12], maintained in
Hanks medium (Sigma-Aldrich Chemie BV, Zwijn-
drecht, The Netherlands), ®fth passage]. The cartilagi-
nous nature of the cell lines was con®rmed using S-100
immunocytochemistry and reverse transcription
polymerase chain reaction (RT-PCR) for the carti-
lage-speci®c gene type II procollagen, as previously
described [13]. Two metastases of central chondrosar-
coma and both the low-grade cartilaginous and the
high-grade anaplastic component (which often metas-
tasizes) of a dedifferentiated chondrosarcoma were
additionally included.
Preparations of lysates
Up to 40 sections (20 mm) were cut from frozen tissue
blocks of the cartilaginous tumour samples, normal
costal cartilage, and testis. The cryostat sections were
subsequently incubated with 200 ml of lysis buffer for
30 min on ice and centrifuged at 16 000 g for 20 min at
4uC. The supernatant was snap-frozen and stored at
x80uC. The protein concentration was determined
using a Bradford assay (Pierce, Rockford, IL, USA).
Lysates of cell lines were prepared using 2r106 cells,
washed in phosphate-buffered saline (PBS), and cen-
trifuged at 3000 g at 4uC. The pellet was suspended in
200 ml of lysis buffer. Lysates were frozen in aliquots
and thawed only once.
TRAP assay
The Telomerase PCR ELISA kit (Boehringer,
Mannheim, Germany), a photometric enzyme immu-
noassay based on the telomeric repeat ampli®cation
protocol (TRAP) of Kim et al. [14], was used to detect
telomerase activity. The assay was performed
according to the manufacturer's instructions. In brief,
two 10 mg protein aliquots were used to perform the
telomerase assay in duplicate. Each aliquot was added
to 25 ml of reaction mix, containing telomerase sub-
strate, biotin-labelled P1-TS primer and P2 primer,
nucleotides, and Taq-polymerase in Tris buffer in a
®nal volume of 50 ml. PCR was carried out in a
programmable heat block (Perkin Elmer, Norwalk,
CT, USA) consisting of P1-TS primer elongation for
30 min at 25uC, telomerase inactivation for 5 min at
94uC, and product ampli®cation by repeat of 30 cycles
of denaturation (30 s at 94uC), annealing (30 s at
45uC), and polymerization (90 s at 72uC). Five micro-
litres of the ampli®cation product was incubated with
20 ml of the denaturation reagent (sodium hydro-
xide<0.5%) for 10 min at room temperature; 225 ml
of hybridization buffer (containing DIG-labelled detec-
tion probe) was added and brie¯y mixed. For each
probe, 100 ml of this mixture was transferred into the
wells of a streptavidin-coated microtitre plate, covered
with the self-adhesive foil provided, and incubated for
2 h at 37uC. The hybridization mixture was removed
and the wells were washed three times with 250 ml of
washing buffer. Then the wells were incubated with
100 ml of anti-DIG-POD working solution (peroxidase-
labelled sheep-anti-DIG to a ®nal concentration of
10 mU/ml) for 30 min at room temperature. The wells
were washed again ®ve times and incubated with 100 ml
of TMB substrate (3,3k,5,5k-tetramethylbenzidine) for
30 min at room temperature. The reaction was stopped
with 100 ml of stop reagent (<5% sulphuric acid).
Immediately afterwards, the absorbance was measured
with a Titerskan Multiskan Plus at 450 nm. Telomer-
ase activity was detected as absorbance at 450 nm
greater than or equal to 0.250, according to the
manufacturer's recommendations.
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The cell lysate provided by the manufacturer served
as a positive control. In addition, 10 mg of testis lysate,
prepared from tissue that was fresh frozen in the same
manner as the chondrosarcoma tissue samples, was
used to exclude the possibility that this process might
inhibit the detection of telomerase. Negative controls
included the addition of RNAse and were performed
for each tumour sample.
Results
TRAP assay
Telomerase activity was not detected in any of the
cartilaginous tumour samples under standard TRAP
assay conditions, using cell lysates containing 10 mg
protein (Table 1). One exception was weak telomerase
activity in a single enchondroma (A450=0.305). Absor-
bance values in the other tumour samples ranged from
0.052 to 0.214. Mean absorbance values per subgroup
are shown in Table 1. Two chondrosarcoma cell lines
(SW-1353 and OUMS-27) both demonstrated telomer-
ase activity (A450=2.334 and 0.871, respectively). A
high-grade chondrosarcoma cell culture and the corre-
sponding frozen tissue sample of the same tumour were
both negative. Also, two metastases tested did not
show any telomerase activity. Interestingly, in the
dedifferentiated chondrosarcoma, both the high-grade
anaplastic component and the low-grade cartilaginous
component failed to show telomerase activity. Non-
A B
Figure 1. Histology of chondrosarcoma samples. (A) Representative slide of a resected specimen of a bulky grade I chondrosarcoma
arising in the left proximal femur. The micrograph displays low cellularity with limited cytonuclear atypia and abundant chondroid
matrix surrounding tumour cells. Scattered binucleated cells are found. (B) Light micrograph of a representative slide of a resected
specimen from the right scapula showing a grade III chondrosarcoma. The micrograph displays high cellularity, cytonuclear atypia, and
myxoid changes. Chondroid matrix is almost absent
Table 1. Mean absorbance values at 450 nm for each subgroup, divided into central and peripheral cartilaginous tumours
Central tumours Mean A450 Peripheral tumours Mean A450
Enchondromas (n=10) 0.115 Osteochondroma (n=5) 0.079
Borderline CS (n=7) 0.085 Borderline CS (n=1) 0.087
Primary CS I (n=6) 0.076 Secondary CS I (n=4) 0.082
Primary CS II (n=11) 0.084
Primary CS III (n=3) 0.065
Secondary CS I (n=4) 0.081
Dedifferentiated CS (n=1)
Cartilaginous component 0.073
Anaplastic component 0.069 Controls Range
Metastases (n=2) 0.087 Positive controls 0.835±2.508
Normal cartilage 0.070 Negative controls 0.048±0.193
CS=chondrosarcoma, I, II, III: tumour grades according to Evans [29]. All tumour samples were negative, since telomerase activity was detected as
absorbance at 450 nm greater than or equal to 0.250. Positive controls included the cell lysate provided by the manufacturer and testis lysate prepared
from fresh frozen tissue.
356 J. V. M. G. BoveÂe et al.
Copyright # 2000 John Wiley & Sons, Ltd. J Pathol 2001; 193: 354±360.
neoplastic costal cartilage failed to show any telomer-
ase activity, as expected (A450=0.070). In addition, one
chondrosarcoma stored at x80uC for only 8 days was
subjected to the telomerase assay. This sample also
failed to show telomerase activity, excluding the lack of
telomerase activity resulting from longer storage of
tissue blocks at x80uC.
Both the cell lysate provided as a positive control by
the manufacturer and the testis lysate demonstrated
high telomerase activity each time the assay was
performed (A450 range 0.835±2.508).
Inhibition tests
Lack of detectable telomerase activity in chondrosar-
coma due to lack of sensitivity of the TRAP assay was
excluded, since the lysis buffer according to Norton
et al. [15], which would yield higher amounts of
telomerase, did not result in detectable telomerase in
three tumour samples. For six tumour samples, the
assay was carried out with a 25-fold increased protein
concentration (250 mg instead of 10 mg), which did not
result in detectable telomerase activity.
Addition of the RNAse inhibitor RNAsin (1 U/ml)
(Promega, Madison, WI, USA) to the lysis buffer prior
to cell lysis [16,17] did not restore telomerase activity in
three chondrosarcoma samples, excluding the possibi-
lity that tumour cells contained high levels of endo-
genous RNAse, resulting in inactivation of telomerase
upon lysis. Two phenol extractions and an ethanol
precipitation prior to the PCR to remove possible Taq
inhibitors [16] did not restore telomerase activity in
three chondrosarcoma samples, suggesting that lack of
detectable telomerase due to Taq-polymerase inhibitors
is less likely.
In order to determine whether the cartilaginous
tumour lysates could inhibit telomerase activity of the
positive control, lysates (10 mg) of 15 tumours
[enchondroma (n=2), chondrosarcoma borderline
(n=3), grade I (n=2), grade II (n=4), grade III
(n=3), and the anaplastic component of the dediffer-
entiated chondrosarcoma] and normal cartilage were
added to 10 mg of testis lysate. Interestingly, a trend
was seen in which the addition of lysate of normal
cartilage and of tumour samples with a high matrix
percentage and low cellularity (as is usually found in
benign and low-grade tumours) resulted in strong
inhibition of telomerase activity. Conversely, tumour
samples with a low matrix percentage and high
cellularity gave less strong inhibition of telomerase
activity (Figure 2). Surprisingly, although the anaplas-
tic component of dedifferentiated chondrosarcoma,
which has high cellularity and no chondroid matrix,
did not show detectable telomerase activity, only
slight inhibition was found in the inhibition assay.
The addition of bovine serum albumin (BSA, grade
V) or lysate buffer did not result in inhibition of
telomerase activity.
Discussion
The development of peripheral chondrosarcoma within
a pre-existing osteochondroma results in genetic
instability, as we previously demonstrated by a high
percentage of loss of heterozygosity (LOH) and a wide
variation in DNA ploidy in peripheral chondrosar-
coma [18]. In contrast, peridiploidy and a low
percentage of LOH in central tumours suggested that
a different oncogenic molecular mechanism, possibly
consisting of a single genetic alteration, may be
operative [18]. Both of the benign precursor lesions,
enchondroma and osteochondroma, have been shown
to be clonal and to show little or no growth [19,20].
Unfortunately, no speci®c immunohistochemical or
molecular genetic markers that characterize the pro-
gression from enchondroma to central chondrosar-
coma or osteochondroma and to peripheral
chondrosarcoma have been found so far to assist in
the differential diagnosis. It is generally considered
dif®cult to distinguish between benign cartilaginous
tumours and low-grade chondrosarcoma [4]. Since all
major types of cancer demonstrate telomerase activity
in the vast majority of cases, whereas telomerase
activity is detected in a much lower percentage of
benign lesions [3], we postulated that reactivation of
telomerase activity would accompany malignant trans-
formation in cartilaginous tumours.
Surprisingly, telomerase activity was not detected in
any of the 52 cartilaginous tumour samples using a
standard TRAP assay, apart from weak activity in a
single enchondroma. Chondrosarcomas generally dis-
play low cellularity, especially in low-grade tumours,
with a low proliferative index [18]. For other tumours,
it was suggested that highly proliferative tumours
display a higher telomerase activity [21]. It is, however,
unlikely that this explains the complete lack of
telomerase activity, since the TRAP assay is highly
sensitive, detecting telomerase activity if as few as 1 in
104 cells in a mixed population has telomerase
expression [14]. We con®rmed the presence of viable
tumour cells by investigation of haematoxylin and
eosin-stained cryostat sections. Increasing the protein
concentration 25-fold did not result in detectable
telomerase activity. In addition, the use of a lysis
buffer prepared according to Norton et al. [15], which
would yield higher amounts of telomerase, failed to
demonstrate telomerase in all chondrosarcoma samples
tested.
Other tumour types with absent or infrequent
telomerase activity have been reported. Lack of
telomerase activity has been described in 50% of
retinoblastomas [22], which was explained by the fact
that retinoblastoma is of embryonic origin and devel-
ops at an early age, when telomeres are still relatively
long [22]. In contrast, chondrosarcoma is a tumour of
late adulthood (on average between 35 and 60 years of
age). In addition, 21 of 21 desmoids [23], 25% of
glioblastomas [24], and nine of ten leiomyosarcomas
[25] were reported to be telomerase-negative. In six
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low-grade soft tissue sarcomas telomerase activity was
absent, while only 19 of 38 (50%) intermediate/high-
grade soft tissue sarcomas demonstrated telomerase
activity [25]. Also, 10±30% of immortal cell lines lack
telomerase expression [16,26,27]. This phenomenon
may be explained by a novel and as yet unidenti®ed
alternative pathway (denoted alternative lengthening of
telomeres, ALT) to maintain telomere length
[16,26,27].
There are two possible explanations for the lack of
detectable telomerase activity in chondrosarcoma.
Either the detection of telomerase is just strongly
inhibited in cartilaginous tumour lysates, or telomerase
activity is truly absent in chondrosarcoma. Eosinophil
or neutrophil granulocytic in®ltrates, described as
inhibiting telomerase detection in Hodgkin's disease
due to the presence of RNAses, are characteristically
absent in chondrosarcomas [17]. Inhibition due to
another endogenous RNAse was excluded as well,
using the addition of an RNAse inhibitor upon cell
lysis. Inhibition of Taq-polymerase was not very likely,
since phenol extractions and an ethanol precipitation
to remove possible Taq inhibitors did not result in the
detection of telomerase. We did, however, demonstrate
the inhibition of detectable telomerase activity of testis
lysate by adding cartilaginous tumour tissue lysates. A
trend was seen for the addition of lysate of normal
cartilage and of tumour samples with a high matrix
percentage and low cellularity (as is usually found in
benign and low-grade tumours) to result in strong
inhibition of telomerase activity. Conversely, tumour
samples with a low matrix percentage and high
cellularity gave less strong inhibition of telomerase
activity (Figure 2). Our results may therefore suggest
that cartilaginous tissue, especially the hyaline cartila-
ginous matrix, may contain unusually strong inhibitory
factors other than endogenous RNAse or Taq-poly-
merase inhibitors, disabling the detection of telomerase
activity using the TRAP assay.
However, we tested two chondrosarcoma cell lines,
OUMS-27 and SW-1353, and both demonstrated
telomerase activity. Chondrosarcoma cell lines are
sparse, since chondrocytes are dif®cult to culture in
vitro, because of their limited proliferation potential.
They usually cease dividing after several generations.
We succeeded in culturing a recurrence of a high-grade
peripheral chondrosarcoma, with almost no chondroid
matrix that had been passaged ®ve times before testing,
which was therefore not yet an established cell line. No
telomerase activity could be detected. Our results
therefore suggest that additional aberrations in vitro
reactivating telomerase would be necessary, in a late
Figure 2. Results of the inhibition assay. On the left axis, the absorbance at 450 nm is demonstrated, represented in bars, whereas
on the right axis, the amount of cartilaginous matrix is demonstrated, estimated as a percentage from the total surface area of the
tissue slide. Due to admixture with normal tissue, ranking of the tumours according to the percentage of hyaline matrix is not
according to histological grade. The left bar represents the positive control of the testis lysate, to which the cartilaginous tumour
lysates were added
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passage during cell culture, to establish a chondrosar-
coma cell line. This may also explain why it is dif®cult
to establish a chondrosarcoma cell line with a
cartilaginous phenotype. Furthermore, the absence of
telomerase in the early passages during high-grade
chondrosarcoma cell culture suggests that telomerase
activity is truly absent in chondrosarcoma.
Surprisingly, although only slight inhibition of
detectable telomerase activity of the testis lysate was
found in the inhibition assay using the anaplastic
component of dedifferentiated chondrosarcoma, no
telomerase activity could be detected. Dedifferentiated
chondrosarcoma consists of a mostly low-grade carti-
laginous and a high-grade anaplastic component, of
which both have been shown to be derived from a
single precursor [28]. The anaplastic component is very
cellular, contains no cartilaginous matrix, and has a
very high metastatic potential. The complete absence
of detectable telomerase activity in the anaplastic
component of dedifferentiated chondrosarcoma, as
well as in high-grade conventional chondrosarcomas,
largely devoid of any cartilaginous matrix, may
additionally favour the possibility that telomerase
activity is truly absent in chondrosarcoma.
In conclusion, we have shown the in vitro inhibitory
effect of a tissue component, probably the cartilagi-
nous matrix, on telomerase activity detection using the
TRAP assay. We have demonstrated the absence of
detectable telomerase activity in benign as well as
malignant cartilaginous tumours, even those with little
or no cartilaginous matrix. However, the lack of
detectable telomerase activity in the high-grade com-
ponent of a dedifferentiated chondrosarcoma without
matrix, and in a high-grade chondrosarcoma cell
culture, favours the possibility that telomerase is truly
absent. Due either to the absence of telomerase in
chondrosarcomas, or to inhibitory effects disabling
telomerase detection, the telomerase TRAP assay is
excluded as a diagnostic tool in the differential
diagnosis of benign and low-grade malignant cartilagi-
nous tumours.
Acknowledgements
We would like to thank Professor M. Namba, Department of
Cell Biology, Okayama University Medical School, Okayama,
Japan, for providing us with the OUMS-27 chondrosarcoma cell
line, and M. A. N. Blonk-Beckers, J. D. H. van Eendenburg, and
C. J. Kruithof for expert technical assistance. This study was
®nancially supported by the Sacha Swarttouw-Hijmans Founda-
tion.
References
1. Klingelhutz AJ. Telomerase activation and cancer. J Mol Med
1997; 75: 45±49.
2. Chiu CP, Harley CB. Replicative senescence and cell immortal-
ity: the role of telomeres and telomerase. Proc Soc Exp Biol Med
1997; 214: 99±106.
3. Shay JW, Bacchetti S. A survey of telomerase activity in human
cancer. Eur J Cancer [A] 1997; 33A: 787±791.
4. Mirra JM, Gold R, Downs J, Eckardt JJ. A new histologic
approach to the differentiation of enchondroma and chondro-
sarcoma of the bones. A clinicopathologic analysis of 51 cases.
Clin Orthop 1985; 201: 214±237.
5. Unni KK. Chondrosarcoma (primary, secondary, dedifferen-
tiated, and clear cell). In Dahlin's Bone Tumors. General Aspects
and Data on 11,087 Cases (5th edn), Unni KK (ed.). Lippinco-
t±Raven Publishers: Philadelphia, 1996; 71±108.
6. Mulder JD, SchuÈ tte HE, Kroon HM, et al. Radiologic Atlas of
Bone Tumors. Elsevier: Amsterdam, 1993.
7. Spring®eld DS, Gebhardt MC, McGuire MH. Chondrosarcoma:
a review. J Bone Jt Surg, Am Vol 1996; 78A: 141±149.
8. Schmale GA, Conrad EU, Raskind WH. The natural history of
hereditary multiple exostoses. J Bone Jt Surg, Am Vol 1994; 76A:
986±992.
9. Wicklund LC, Pauli RM, Johnston D, Hecht JT. Natural history
study of hereditary multiple exostoses. Am J Med Genet 1995; 55:
43±46.
10. Huvos AG. Bone Tumors. Diagnosis, Treatment, and Prognosis
(2nd edn). W. B. Saunders: Philadelphia, 1991.
11. Kunisada T, Miyazaki M, Mihara K, et al. A new human
chondrosarcoma cell line (OUMS-27) that maintains chondrocy-
tic differentiation. Int J Cancer 1998; 77: 854±859.
12. Koopman LA, Szuhai K, Eendenburg van JDH, et al. Recurrent
integration of human papillomaviruses 16, 45, and 67 near
translocation breakpoints in new cervical cancer cell lines.
Cancer Res 1999; 59: 5615±5624.
13. Chano T, Okabe H, Saeki Y, Ishizawa M, Matsumoto K,
Hukuda S. Characterization of a newly established human
chondrosarcoma cell line, CS-OKB. Virchows Arch [A] 1998;
432: 529±534.
14. Kim NW, Piatyszek MA, Prowse KR, et al. Speci®c association
of human telomerase activity with immortal cells and cancer.
Science 1994; 266: 2011±2015.
15. Norton JC, Holt SE, Wright WE, Shay JW. Enhanced detection
of human telomerase activity. DNA Cell Biol 1998; 17:
217±219.
16. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR.
Telomere elongation in immortal human cells without detectable
telomerase activity. EMBO J 1995; 14: 4240±4248.
17. Norrback K, Enblad G, Erlanson M, Sundstrom C, Roos G.
Telomerase activity in Hodgkin's disease. Blood 1998; 92:
567±573.
18. Bovee JVMG, Cleton-Jansen AM, Kuipers-Dijkshoorn N, et al.
Loss of heterozygosity and DNA ploidy point to a diverging
genetic mechanism in the origin of peripheral and central
chondrosarcoma. Genes Chromosomes Cancer 1999; 26:
237±246.
19. Bovee JVMG, Cleton-Jansen AM, Wuyts W, et al. EXT-
mutation analysis and loss of heterozygosity in sporadic and
hereditary osteochondromas and secondary chondrosarcomas.
Am J Hum Genet 1999; 65: 689±698.
20. Sandberg AA, Bridge JA. The Cytogenetics of Bone and Soft
Tissue Tumors. R. G. Landes: Austin, TX, 1994.
21. Holt SE, Wright WE, Shay JW. Multiple pathways for the
regulation of telomerase activity. Eur J Cancer [A] 1997; 33A:
761±766.
22. Gupta J, Han LP, Wang P, Gallie BL, Bacchetti S. Development
of retinoblastoma in the absence of telomerase activity. J Natl
Cancer Inst 1996; 88: 1152±1157.
23. Scates DK, Clark SK, Phillips RKS, Venitt S. Lack of
telomerase in desmoids occurring sporadically and in association
with familial adenomatous polyposis. Br J Surg 1998; 85:
965±969.
24. Langford LA, Piatyszek MA, Xu R, Schold SC, Shay JW.
Telomerase activity in human brain tumours. Lancet 1995; 346:
1267±1268.
25. Yan P, Coindre JM, Benhattar J, Bosman FT, Guillou L.
Telomerase activity and human telomerase reverse transcriptase
mRNA expression in soft tissue tumors: correlation with grade,
Telomerase not detectable in chondrosarcoma 359
Copyright # 2000 John Wiley & Sons, Ltd. J Pathol 2001; 193: 354±360.
histology, and proliferative activity. Cancer Res 1999; 59:
3166±3170.
26. Ogino H, Nakabayashi K, Suzuki M, et al. Release of telomeric
DNA from chromosomes in immortal human cells lacking
telomerase activity. Biochem Biophys Res Commun 1998; 248:
223±227.
27. Wen J, Cong Y, Bacchetti S. Reconstitution of wild-type or
mutant telomerase activity in telomerase-negative
immortal human cells. Hum Mol Genet 1998; 7: 1137±1141.
28. Bovee JVMG, Cleton-Jansen AM, Rosenberg C, Taminiau
AHM, Cornelisse CJ, Hogendoorn PCW. Molecular genetic
characterization of both components of a dedifferentiated
chondrosarcoma, with implications for its histogenesis. J Pathol
1999; 189: 454±462.
29. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in
chondrosarcoma of bone. A clinicopathologic analysis with
emphasis on histologic grading. Cancer 1977; 40: 818±831.
360 J. V. M. G. BoveÂe et al.
Copyright # 2000 John Wiley & Sons, Ltd. J Pathol 2001; 193: 354±360.
